Biocad is ready to consider the possibility of producing Sputnik V in nasal spray form


Biocad biotech company is ready to consider the possibility of producing Sputnik V, a vaccine against the coronavirus infection, in nasal spray form, if a corresponding request is received from the Gamaleya Center. This is reported by TASS with reference to Alexey Torgov, Deputy General Director for Corporate Relations and Communications of the company.

“We are ready to consider production when we receive a request from the Gamaleya Center about the possibility of including ZAO Biocad as a contract production site,” he said, answering a question about the possibility of supplying Sputnik V in nasal form.

The Ministry of Health of the Russian Federation previously allowed testing of a nasal spray vaccine against coronavirus infection developed by the Gamaleya Center.

In September 2020, Biocad signed an agreement with the Gamaleya Center on the commercial release of Sputnik V COVID-19 vaccine. According to the company’s CEO Dmitry Morozov, the company was able to quickly launch additional lines for the production of vaccines, the volume of investments amounting to about 500 million rubles. In the spring of 2021, Biocad reached the monthly production volume of Sputnik V at two million doses, and in the summer it planned to increase this figure to five to six million doses per month. In September this year, by order of the Ministry of Health, the company began producing the Sputnik Lite coronavirus vaccine.